{"nctId":"NCT01357356","briefTitle":"Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia","startDateStruct":{"date":"2011-05"},"conditions":["Nocturia"],"count":750,"armGroups":[{"label":"SER120 (750 ng/day)","type":"EXPERIMENTAL","interventionNames":["Drug: SER120 (750 ng/day)"]},{"label":"SER120 (1000 ng/day)","type":"EXPERIMENTAL","interventionNames":["Drug: SER120 (1000 ng/day)"]},{"label":"SER120 (1500 ng/day)","type":"EXPERIMENTAL","interventionNames":["Drug: SER120 (1500 ng/day)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SER120 (750 ng/day)","otherNames":[]},{"name":"SER120 (1000 ng/day)","otherNames":[]},{"name":"SER120 (1500 ng/day)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female 50 years or older\n* Nocturia of 6 or more months duration averaging greater than 2 nocturic episode per night\n\nExclusion Criteria:\n\n* CHF\n* Diabetis Insipidus\n* Renal Insufficiency\n* Hepatic Insufficiency\n* Incontinence\n* Illness requiring systemic steroids\n* Malignancy within the past 5 years\n* Sleep Apnea\n* Nephrotic Syndrome\n* Unexplained Pelvic Mass\n* Urinary Bladder Neurological dysfunction\n* Urinary Bladder Surgery or Radiotherapy\n* Pregnant or Breast Feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in # of Mean Nocturic Episodes Per Night","description":"Change was calculated based on the number of mean nocturic episodes per night between baseline through week 12","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"0.07"},{"groupId":"OG001","value":"-1.4","spread":"0.07"},{"groupId":"OG002","value":"-1.6","spread":"0.07"},{"groupId":"OG003","value":"-1.2","spread":"0.07"}]}]}]},{"type":"PRIMARY","title":"Percent of Participants With 50% or Greater in Reduction of Nocturic Episodes","description":"Percent of participants achieving at least 50% reduction in mean nocturic episode per night during 12 weeks compared to baseline","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"61","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":188},"commonTop":["Nasal discomfort","Headache","Hypertension"]}}}